Marta Massanella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3988232/publications.pdf

Version: 2024-02-01

80 papers 3,609 citations

30 h-index 57 g-index

88 all docs 88 docs citations

88 times ranked 5249 citing authors

#	Article	IF	Citations
1	Inappropriate sinus tachycardia in post-COVID-19 syndrome. Scientific Reports, 2022, 12, 298.	3.3	57
2	Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission. Scientific Reports, 2022, 12, 640.	3.3	11
3	Small form factor flow virometer for SARS-CoV-2. Biomedical Optics Express, 2022, 13, 1609.	2.9	3
4	Clinical course impacts early kinetics, magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine, 2022, 3, 100523.	6.5	18
5	Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities. Age and Ageing, 2022, 51, .	1.6	7
6	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. Frontiers in Immunology, 2022, 13, .	4.8	2
7	Neurocognitive Profile of the Post-COVID Condition in Adults in Catalonia—A Mixed Method Prospective Cohort and Nested Case–Control Study: Study Protocol. Vaccines, 2022, 10, 849.	4.4	1
8	Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, 427-438.	5.8	13
9	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Scientific Reports, 2021, 11, 2608.	3.3	86
10	Stable neutralizing antibody levels 6Âmonths after mild and severe COVID-19 episodes. Med, 2021, 2, 313-320.e4.	4.4	77
11	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine, 2021, 65, 103270.	6.1	46
12	Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in NaÃ⁻ve HIV-1–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, e146-e149.	2.1	0
13	Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet Microbe, The, 2021, 2, e198-e209.	7.3	24
14	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. Viruses, 2021, 13, 1135.	3.3	17
15	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. Open Forum Infectious Diseases, 2021, 8, ofab329.	0.9	7
16	SARS-CoV-2 Infection Modulates ACE2 Function and Subsequent Inflammatory Responses in Swabs and Plasma of COVID-19 Patients. Viruses, 2021, 13, 1715.	3.3	14
17	TL1A–DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1–Specific T Cell Responses. Journal of Immunology, 2020, 205, 3348-3357.	0.8	3
18	Improving HIV Outgrowth by Optimizing Cell-Culture Conditions and Supplementing With all-trans Retinoic Acid. Frontiers in Microbiology, 2020, 11, 902.	3.5	15

#	Article	IF	CITATIONS
19	Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy. Journal of Virology, 2019, 94, .	3.4	23
20	Subclinical Cytomegalovirus DNA Is Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in People Living with HIV despite Early Antiretroviral Therapy. Journal of Virology, 2019, 93, .	3.4	27
21	Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. PLoS Pathogens, 2019, 15, e1007619.	4.7	177
22	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. PLoS Computational Biology, 2019, 15, e1006849.	3.2	22
23	Replication competence of virions induced from CD4+ lymphocytes latently infected with HIV. Retrovirology, 2019, 16, 4.	2.0	6
24	Memory B cell dysregulation in HIV-1-infected individuals. Aids, 2018, 32, 149-160.	2.2	11
25	Analyses of Mitochondrial DNA and Immune Phenotyping Suggest Accelerated T-Cell Turnover in Treated HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 399-406.	2.1	0
26	Improved assays to measure and characterize the inducible HIV reservoir. EBioMedicine, 2018, 36, 113-121.	6.1	47
27	Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise. Retrovirology, 2018, 15, 9.	2.0	25
28	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 201-205.	2.1	7
29	Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types. Journal of Clinical Microbiology, 2017, 55, 2544-2553.	3.9	16
30	Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. Scientific Reports, 2017, 7, 11711.	3.3	12
31	Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. Nature Protocols, 2017, 12, 2029-2049.	12.0	55
32	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS ONE, 2017, 12, e0184433.	2.5	17
33	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 133-137.	2.1	17
34	Residual inflammation and viral reservoirs. Current Opinion in HIV and AIDS, 2016, 11, 234-241.	3.8	107
35	Effects of HIV/TAT protein expression and chronic selegiline treatment on spatial memory, reversal learning and neurotransmitter levels in mice. Behavioural Brain Research, 2016, 311, 131-140.	2.2	28
36	Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host and Microbe, 2016, 20, 368-380.	11.0	170

#	Article	IF	Citations
37	Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART. Retrovirology, 2016, 13, 51.	2.0	14
38	Standard vaccines increase HIV-1 transcription during antiretroviral therapy. Aids, 2016, 30, 2289-2298.	2.2	30
39	Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes. Aids, 2016, 30, 2275-2287.	2.2	10
40	Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. Journal of Virology, 2016, 90, 3944-3952.	3.4	52
41	Microstructural changes to the brain of mice after methamphetamine exposure as identified with diffusion tensor imaging. Psychiatry Research - Neuroimaging, 2016, 249, 27-37.	1.8	7
42	Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. Journal of NeuroVirology, 2016, 22, 191-200.	2.1	31
43	Measuring the latent reservoir in vivo. Journal of Clinical Investigation, 2016, 126, 464-472.	8.2	76
44	Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Scientific Reports, 2015, 5, 13179.	3.3	45
45	Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. Journal of Translational Medicine, 2015, 13, 230.	4.4	33
46	The Sordid Affair Between Human Herpesvirus and HIV. Journal of Infectious Diseases, 2015, 212, 845-852.	4.0	75
47	Quantification of HIV RNA and Human Herpesvirus DNA in Seminal Plasma. Bio-protocol, 2015, 5, .	0.4	7
48	Quantification of Total and 2-LTR (Long terminal repeat) HIV DNA, HIV RNA and Herpesvirus DNA in PBMCs. Bio-protocol, 2015, 5, .	0.4	26
49	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. PLoS ONE, 2014, 9, e114142.	2.5	27
50	Cytomegalovirus Replication in Semen Is Associated with Higher Levels of Proviral HIV DNA and CD4 ⁺ T Cell Activation during Antiretroviral Treatment. Journal of Virology, 2014, 88, 7818-7827.	3.4	69
51	The effect of cell subset isolation method on gene expression in leukocytes. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 94-104.	1.5	63
52	A case cluster demonstrating the relationship between HLA concordance and virologic and disease outcomes in human immunodeficiency virus infection. Virology, 2014, 449, 104-108.	2.4	1
53	Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. Aids, 2014, 28, 325-334.	2.2	62
54	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. PLoS ONE, 2014, 9, e87334.	2.5	15

#	Article	IF	CITATIONS
55	Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. Journal of Translational Medicine, 2013, 11, 68.	4.4	92
56	Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 648-658.	1.5	13
57	Differential gene expression in HIV-infected individuals following ART. Antiviral Research, 2013, 100, 420-428.	4.1	32
58	Attacking the HIV Reservoir from the Immune and Viral Perspective. Current HIV/AIDS Reports, 2013, 10, 33-41.	3.1	15
59	Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. Aids, 2013, 27, 1921-1931.	2.2	104
60	Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 152-160.	2.1	21
61	Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2358-2362.	3.0	28
62	HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. Aids, 2013, 27, 1375-1385.	2.2	15
63	Immunodiscordant responses to HAART – mechanisms and consequences. Expert Review of Clinical Immunology, 2013, 9, 1135-1149.	3.0	79
64	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. Antiviral Therapy, 2012, 17, 355-364.	1.0	108
65	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. Aids, 2012, 26, 2285-2293.	2.2	44
66	Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function. PLoS ONE, 2012, 7, e30330.	2.5	13
67	Susceptibility of Human Lymphoid Tissue Cultured ex vivo to Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Infection. PLoS ONE, 2012, 7, e37415.	2.5	2
68	Adenosine Deaminase Enhances the Immunogenicity of Human Dendritic Cells from Healthy and HIV-Infected Individuals. PLoS ONE, 2012, 7, e51287.	2.5	21
69	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	3.8	38
70	The reconstitution of the thymus in immunosuppressed individuals restores CD4â€specific cellular and humoral immune responses. Immunology, 2011, 133, 318-328.	4.4	12
71	Restricted infection of xenotropic murine leukemia virus-related virus in human lymphoid tissue. Retrovirology, 2011, 8, .	2.0	0
72	Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART. PLoS Pathogens, 2011, 7, e1002314.	4.7	55

#	Article	IF	CITATIONS
73	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 2011, 121, 2391-2400.	8.2	168
74	Changes in T-cell subsets in HIV–HCV-coinfected patients during pegylated interferon-α2a plus ribavirin treatment. Antiviral Therapy, 2010, 15, 333-342.	1.0	16
75	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Medicine, 2010, 16, 460-465.	30.7	500
76	Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIVâ€Infected Patients: Clinical Implications. Clinical Infectious Diseases, 2010, 50, 1300-1308.	5.8	133
77	CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. Aids, 2010, 24, 959-968.	2.2	114
78	On the steps of cell-to-cell HIV transmission between CD4 T cells. Retrovirology, 2009, 6, 89.	2.0	38
79	Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. Aids, 2009, 23, 183-188.	2.2	70
80	HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology, 2008, 5, 32.	2.0	46